血管內皮生長因子-D 對淋巴管平滑肌瘤病診治價值的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

廖新 ,  況九龍

南昌大學第二附屬醫院呼吸與危重癥醫學科（江西南昌 330006）;

Corresponding?author：

況九龍, Email: kuangjl1957@126.com

Keywords：

DOI：

10.7507/1671-6205.201808030

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 廖新, 況九龍. 血管內皮生長因子-D 對淋巴管平滑肌瘤病診治價值的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(6): 603-605. doi: 10.7507/1671-6205.201808030 Copy

1.	Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J, 2010, 35(1): 14-26.
2.	徐凱峰, 胡曉文, 朱元玨. 歐洲呼吸病學會淋巴管肌瘤病指南解讀. 中華結核和呼吸雜志, 2010, 33(12): 884-886.
3.	趙天明, 倪吉祥, 胡學華. 淋巴管平滑肌瘤病最新研究進展. 中國全科醫學, 2017, 20(24): 3056-3062.
4.	McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
5.	胡曉文, 朱建榮, 徐凱峰. 1981 年至 2009 年中國淋巴管肌瘤病文獻資料匯總分析. 中國呼吸與危重監護雜志, 2010, 9(5): 508-511.
6.	張龍舉, 梁毅, 鐘小寧, 等. 國內三十余年肺淋巴管肌瘤病 130 例臨床與病理文獻復習分析. 中國全科醫學, 2015, 18(3): 329-334.
7.	Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A, 1995, 92(8): 3566-3570.
8.	Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A, 1998, 95(2): 548-553.
9.	Issaka RB, Oommen S, Gupta SK, et al. Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol, 2009, 175(4): 1410-1420.
10.	Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348.
11.	Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol, 2006, 4(3): 143-152.
12.	Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med, 2008, 358(2): 199-200.
13.	Young LR, Lee HS, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med, 2013, 1(6): 445-452.
14.	Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med, 2013, 107(2): 263-268.
15.	Glasgow CG, Avila NA, Lin JP. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest, 2009, 135(5): 1293-1300.
16.	Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res, 2012, 13: 34.
17.	Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest, 2010, 138(3): 674-681.
18.	Radzikowska E, Jagu? P, Skoczylas A, et al. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn, 2013, 123(10): 533-538.
19.	Mou Y, Ye L, Wang J, et al. Diagnostic and treatment monitoring potential of serum vascular endothelial growth factor-D in lymphangioleiomyomatosis. Lymphology, 2016, 49(3): 140-149.
20.	Radzikowska E, Jagu? P, Sobiecka M, et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med, 2015, 109(11): 1469-1475.
21.	McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med, 2011, 364(17): 1595-1606.
22.	Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. Chest, 2018, 153(1): 124-132.
23.	Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell, 2010, 40(2): 310-322.
24.	Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase Ⅱ study. Eur Respir J, 2015, 46(3): 783-794.

1. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J, 2010, 35(1): 14-26.
2. 徐凱峰, 胡曉文, 朱元玨. 歐洲呼吸病學會淋巴管肌瘤病指南解讀. 中華結核和呼吸雜志, 2010, 33(12): 884-886.
3. 趙天明, 倪吉祥, 胡學華. 淋巴管平滑肌瘤病最新研究進展. 中國全科醫學, 2017, 20(24): 3056-3062.
4. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
5. 胡曉文, 朱建榮, 徐凱峰. 1981 年至 2009 年中國淋巴管肌瘤病文獻資料匯總分析. 中國呼吸與危重監護雜志, 2010, 9(5): 508-511.
6. 張龍舉, 梁毅, 鐘小寧, 等. 國內三十余年肺淋巴管肌瘤病 130 例臨床與病理文獻復習分析. 中國全科醫學, 2015, 18(3): 329-334.
7. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A, 1995, 92(8): 3566-3570.
8. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A, 1998, 95(2): 548-553.
9. Issaka RB, Oommen S, Gupta SK, et al. Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol, 2009, 175(4): 1410-1420.
10. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348.
11. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol, 2006, 4(3): 143-152.
12. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med, 2008, 358(2): 199-200.
13. Young LR, Lee HS, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med, 2013, 1(6): 445-452.
14. Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med, 2013, 107(2): 263-268.
15. Glasgow CG, Avila NA, Lin JP. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest, 2009, 135(5): 1293-1300.
16. Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res, 2012, 13: 34.
17. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest, 2010, 138(3): 674-681.
18. Radzikowska E, Jagu? P, Skoczylas A, et al. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn, 2013, 123(10): 533-538.
19. Mou Y, Ye L, Wang J, et al. Diagnostic and treatment monitoring potential of serum vascular endothelial growth factor-D in lymphangioleiomyomatosis. Lymphology, 2016, 49(3): 140-149.
20. Radzikowska E, Jagu? P, Sobiecka M, et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med, 2015, 109(11): 1469-1475.
21. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med, 2011, 364(17): 1595-1606.
22. Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. Chest, 2018, 153(1): 124-132.
23. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell, 2010, 40(2): 310-322.
24. Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase Ⅱ study. Eur Respir J, 2015, 46(3): 783-794.

Previous Article
經皮球囊肺動脈成形術在慢性血栓栓塞性肺動脈高壓中的應用

Chinese Journal of Respiratory and Critical Care Medicine

血管內皮生長因子-D 對淋巴管平滑肌瘤病診治價值的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content